2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.01 Real-World First-Line Maintenance Immunotherapy for Nonsquamous Advanced/Metastatic NSCLC without Targetable Mutations

P4.11E.01 Real-World First-Line Maintenance Immunotherapy for Nonsquamous Advanced/Metastatic NSCLC without Targetable Mutations

Back to course

Pdf Summary

The study examines real-world data on first-line maintenance immunotherapy (1LMT) for patients with advanced/metastatic non-squamous non-small cell lung cancer (NSQ a/mNSCLC) without targetable genetic mutations. Conducted across multiple countries, the retrospective observational study analyzed patients who completed first-line (1L) induction therapy with platinum-based chemotherapy and immunotherapy (IO), with or without pemetrexed, between January 2019 and March 2021.<br /><br />The study involved 469 patients who achieved complete response (CR), partial response (PR), or stable disease (SD) after 1L induction therapy. These patients were then given 1LMT in the form of IO monotherapy or IO combined with pemetrexed. The outcomes assessed included progression-free survival (PFS), overall survival (OS), time to discontinuation (TTD), and adverse events (AE).<br /><br />The results demonstrated that patients receiving IO monotherapy had longer median PFS and OS compared to those receiving IO with pemetrexed. Specifically, IO monotherapy showed median PFS of 21.1 months and OS of 35.3 months, compared to 11.1 months and 27.3 months, respectively, for IO with pemetrexed. Fatigue and anemia were more prevalent in patients treated with IO and pemetrexed. <br /><br />Overall, the study concludes that the addition of pemetrexed to IO 1LMT did not provide a notable clinical benefit in NSQ a/mNSCLC patients, emphasizing the need for more effective 1LMT options. The safety profile of IO monotherapy was comparable to that of the combination treatment, with certain side effects like fatigue and anemia being more common in the latter. These findings highlight the ongoing challenges in treating NSQ a/mNSCLC and the critical need for novel and improved treatment strategies.

Asset Subtitle

Manasee Shah

Meta Tag

Speaker Manasee Shah

Topic Metastatic NSCLC – Immunotherapy

Keywords

immunotherapy

non-small cell lung cancer

first-line maintenance

real-world data

progression-free survival

overall survival

platinum-based chemotherapy

pemetrexed

adverse events

treatment strategies